Moderna Inc. Announces Positive Phase 3 Results for mRNA-1010, Demonstrating Superior Efficacy in Seasonal Influenza Vaccine for Older Adults

Reuters
30 Jun
Moderna Inc. Announces Positive Phase 3 Results for mRNA-1010, Demonstrating Superior Efficacy in Seasonal Influenza Vaccine for Older Adults

Moderna Inc. has announced positive results from a Phase 3 efficacy study of its seasonal influenza vaccine candidate, mRNA-1010. The study, which compared mRNA-1010 to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older, demonstrated a superior relative vaccine efficacy of 26.6% in the overall study population. The vaccine candidate showed strong efficacy against various influenza strains, including A/H1N1, A/H3N2, and the B/Victoria lineages. Safety and tolerability were consistent with previous studies, with most adverse reactions being mild and no significant differences observed in the rates of adverse events between groups. Moderna plans to present these findings at an upcoming medical conference and will engage with regulators on filing submissions for mRNA-1010.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044119) on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10